GlassScriptPhysician profile
Maximilian Psolka
NPI 1255441952
$2,636.19
in general payments reported to CMS, 2019-2025
18 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $209 · 2021: $627 · 2022: $273 · 2023: $186 · 2024: $502 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,096.31 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $432.38 | 2019-2024 | Tecnis Simplicity, Tecnis Iol |
| Kala Pharmaceuticals, INC. | $208.53 | 2019-2020 | |
| Rxsight INC | $189.49 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Ivantis, INC | $150.00 | 2019 | |
| Bausch & Lomb Americas INC. | $105.85 | 2023-2025 | Envista Mx60 Iol, Envista Envy, Envista Envy Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $95.66 | 2019-2020 | |
| Glaukos Corporation | $78.96 | 2023-2025 | Idose, Istent Trabecular Micro-Bypass System Model Is3, Istent |
| Abbvie INC. | $68.63 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $55.20 | 2019 | |
| Carl Zeiss Meditec, INC. | $31.60 | 2019 | |
| Biotissue Holdings INC. | $29.31 | 2025 | |
| Thea Pharma INC. | $19.13 | 2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $15.47 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.15 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $15.14 | 2024 | Xdemvy |
| Allergan, INC. | $15.05 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maximilian Psolka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.